Treatments are more effective and better tolerated by patients
24 PROTOCOLS APPROVED
• Gercor has undertaken 5 phase III studies into colorectal cancer:
– 3 adjuvant studies:
• C96-1 (905 patients included),
• CPT-V 307 (207 patients included),
• MOSAIC (2200 patients included,
450 of which in France): less toxicity in innovative treatment and an increased PFS have been shown
– 2 studies in metastatic situation
• FOLFOX-FOLFIRI vs FOLFIRIFOLFOX/C97-3 (226 patients included),
• OPTIMOX, therapeutic strategy’s trial in metastatic colorectal cancer (623 patients included).
• Gercor has undertaken 1 phase III study into pancreatic cancer :
GEM-GEMOX (326 patients included).
• Gercor has undertaken 1 phase III study into lung cancer : BOO 1 (74 patients included).
• Gercor has participated in 1 BCIRG phase III study in breast cancer :
BCIRG 005 (37 patients included).
• Gercor has conducted 15 phase II
studies:
– 4 studies on colorectal cancer
– 4 studies on pancreatic cancer
– 1 study on lung cancer
– 2 studies on breast cancer
– 1 study on oesophagus cancer
– 1 study on prostate cancer
– 1 study on bladder cancer
– 1 study on stomach cancer
A longer life expectancy
A better quality of life during the illness
Less toxicity or side effects from treatment
12 PROTOCOLS IN PROGRESS,
• Gercor is participating in 4 phase III
trials
– OPTIMOX 2 CO2-2 (colorectal cancer)
– MIROX (colorectal cancer)
– AERO R98 (rectal cancer)
– BCIRG 006 (breast cancer)
• In addition, Gercor is conducting 8 phase II trials in various cancers including 4 in digestive cancers:
– 1 in oesophageal cancer,
– 2 in pancreatic cancer,
– 3 in lung cancer,
– 1 in ovarian cancer,
– 1 in all cancers.
12 PROTOCOLS IN PREPARATION
• 3 phase III protocols and 9 phase II protocole are currently in preparation, treating:
– colon: 4
– stomach: 3
– breast: 1
– pancreas: 1
– mesothelioma: 1
– lung: 1
– thrombosis prevention: 1